Subsequent pregnancy outcomes among women with tubal ectopic pregnancy treated with methotrexate

Scott c Mackenzie, Catherine a Moakes, W colin Duncan, Stephen Tong, Andrew w Horne

Research output: Contribution to journalArticlepeer-review

Abstract / Description of output

An ectopic pregnancy occurs when an embryo implants outside of the uterus, usually in a fallopian tube. When detected
early, treatment is often with a medication called methotrexate. When methotrexate does not work, surgery is required. A
recent clinical trial of ectopic pregnancy treatment (called GEM3) found that adding a drug called gefitinib to methotrexate
did not reduce the need for surgery. We have used data from the GEM3 trial, combined with data collected 12 months
after the trial finished, to investigate post-methotrexate pregnancy outcomes. We found no difference in pregnancy
rates, pregnancy loss rates and recurrent ectopic pregnancy rates between those treated medically only and those who
subsequently also needed surgery. The surgical technique used also did not affect pregnancy rates. This research provides reassurance that women with ectopic pregnancies treated medically who need surgery have similar post-treatment
pregnancy outcomes to those treated successfully medically
Original languageEnglish
JournalReproduction and Fertility
Issue number2
Publication statusPublished - 15 Jun 2023

Keywords / Materials (for Non-textual outputs)

  • tubal ectopic pregnancy
  • methotrexate
  • pregnancy outcomes
  • recurrence
  • risk factor


Dive into the research topics of 'Subsequent pregnancy outcomes among women with tubal ectopic pregnancy treated with methotrexate'. Together they form a unique fingerprint.

Cite this